Authors
Sukovatykh B.S.1, Sukovatykh M.B.1, Grigoryan A.Y.1, Gordov M.Y.2
1 Kursk State Medical University, Kursk
2 Kursk City Clinical Hospital of Emergency Medical Care, Kursk
Abstract
The aim is to compare the efficacy and safety of rivaroxaban and apixaban in the treatment of deep vein thrombosis of the lower extremities in elderly and senile people suffering from chronic obliterating atherosclerosis of the arteries of the lower extremities.
Materials and methods. The results of treatment of 60 elderly and senile patients suffering from obliterating atherosclerosis of the arteries of the lower extremities, who developed deep vein thrombosis, were retrospectively studied. The patients were divided into 2 statistically homogeneous groups of 30 people each. The intergroup difference was the choice of the drug for long-term anticoagulant therapy. In the first group, anticoagulant therapy was performed with apixaban, and in the second group with rivaroxaban. The results of treatment were evaluated after one year by a control ultrasound and clinical examination to determine the degree of restoration of the deep vein lumen and the severity of venous outflow disorders. The frequency of hemorrhagic syndrome was recorded.
Results. After one year, effective recanalization (complete +partial) in the first group occurred in 24 (80%), and in the second — in 29 (96.7%), occlusion developed in 6 (20%) and 1 (3.3%) patients, respectively. Good one-year clinical results (degree of impairment is weak or absent) 18 (60%) patients were registered in the first group, and 24 (80%) patients in the second group. Poor results (the degree of impairment is medium and severe) were found in the first group of u12 (40%).and in the second group -in 6 (20%) patients. Hemorrhagic complications of anticoagulant therapy developed in 8 (13.2%) patients equally in both groups.
Conclusion. Revaroxaban is more effective than apixaban, and there are no differences between the drugs in terms of safety.
Keywords: thrombosis, deep veins, obliterating atherosclerosis of the arteries, lower extremities, apixaban, rivaroxaban.
References
1. Galanaud J, Genty С, Sevestre М, et al. Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis: The OPTIMEV study. Thromb Haemost. 2011; 105 (1): 31-39.
2. Pasechnik IN. The use of new oral anticoagulants in surgery. Part 1. Hirurgiya. 2016; 2: 72-75. (In Russ.) doi: 10.17116/хирургия2016272-75.
3. Kalinin RE, Suchkov IA, Agapov AB. The Effectiveness of the Various Options of Anticoagulant Therapy for the Treatment of the Patients with Thrombosis of the Deep Veins of the Lower Extremities in the Routine Clinical Practice. Flebologiia. 2017; 1(1): 21-27. (In Russ.) doi:10.17116/flebo201711121-27
4. Vorobieva NM, Panchenko EP. Apixaban: new opportunities in the treatment of venous thromboembolic complications. Novosti kardiologii. 2015; 2: 10-13. (In Russ.)
5. Fokin AA, Trejger GA. Novye vozmozhnosti antitromboticheskoj terapii, uluchshayushchie prognoz u pacientov so stenoziruyushchim aterosklerozom sonnyh arterij. Angiologiya i sosudistaya hirurgiya. 2020; 28(2): 17-21. (In Russ.)
6. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications (VTEC). Phlebology. 2015; 9(4): 4-52. (In Russ.)
7. Christopher RL, Kalodiki E, Mustapha A, Geroulakos G. Validation of the Villalta scale in assessing post-thrombotic syndrome using clinical, duplex, and hemodynamic comparators Journal of vascular surgery: Venous and lymphatic disorders. 2014; 2(1): 8-14.
8. Chinsakchai K, Ten Duis K, Moll FL, de Borst GJ. Trends in management of phlegmasia cerulea dolens. Vasc Endovascular Surg. 2011; 45(1): 5-14. doi: 10.1177/1538574410388309.
9. Gel’cer IV., Smirnova OA, Matvienko OYU, Kobelyanskaya VA, Golovina OG, Papayan LP. Osobennosti dejstviya peroral’nyh antikoagulyantov. Serdce: zhurnal dlya praktikuyushchih vrachej. 2015; 14(3): 153-157. (In Russ.)
10. Bredihin RA, Krepkogorskij NV, Hajrullin RN. Est’ li al’ternativy dvojnoj dezagregantnoj terapii posle stentirovaniya perefiricheskih arterij? Angiologiya i sosudistaya hirurgiya. 2021; 27(3): 22-27. (In Russ.)
